BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

British Journal of Cancer

Volumn 82, Issue 2, 2000, Pages 436-440

  Beale, P J ^a   Rogers, P ^a   Boxall, F ^a   Sharp, S Y ^a   Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BCL 2; Ovarian carcinoma; Platinum; Resistance

Indexed keywords

CISPLATIN; PLATINUM; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; TUBULIN;

ARTICLE; CANCER INHIBITION; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; VECTOR CONTROL; XENOGRAFT;

EID: 0033965759     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0939     Document Type: Article

References (12)

1. Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192-196
2. Eliopoulos A, Kerr D, Herod J, Hodgkins, Krajewski S, Reed J and Young L (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228
3. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184
4. Holford J, Sharp SY, Murrer BA, Abrams M and Kelland LR (1998) In vitro circumvention of cisplatin-resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77: 366-373
5. Jones M, Siracky J, Kelland LR and Harrap KR (1993) Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer 67: 24-29
6. Jones NA, Turner J, McIlwrath AJ, Brown R and Dive C (1998) Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819-826
7. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR (1992a) Mechanism-related circumvention of acquired cis-diamminedichloro platinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarhoxylates. Cancer Res 52: 3857-3864
8. Kelland LR, Jones M, Abel G, Valenti M, Gwynne JJ and Harrap KR (1992b) Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Canc Chemother Pharmacol 30: 43-50
9. Lock RB and Stribinskiene L (1996) Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006-4012
10. Ormerod MG, O'Neill C, Robertson D, Kelland LR and Harrap KR (1996) Cis-Diamminedichloro platinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37: 463-471
11. Reed JC (1997) BCL-2 family proteins: role in dysregulation of apoptosis and chemoresistance in cancer. In: Apoptosis and Cancer, Martin SJ (ed), pp. 64-97. Karger-Landes Systems: Basel
12. Yin DX and Schimke RT (1995) BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55: 4922-4928